Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study

Dingwei Ye; Marniza Saad; Ji Youl Lee; Wonho Jung; See‐Tong Pang; Lei Li; Howard Gurney; Gerhardt Attard; Kim N. Chi; Suneel Mundle; Jianmin Zhuo; Anildeep Singh; Yun Lin; Shahneen Sandhu

doi:10.1111/iju.70455

April 1, 2026International Journal of Urology

Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study

View at Publisher

Ask AI

Bookmark

Share

Key Points

Assess the effects of niraparib combined with abiraterone acetate and prednisone in patients with specific genetic alterations and prostate cancer.
Participants included those with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.
The therapy regimen consisted of niraparib, abiraterone acetate, and prednisone.
Final analysis of the Asian subgroup from the MAGNITUDE study.
The combination therapy demonstrated improved clinical outcomes compared to standard treatments.
Significant response rates were noted among patients with homologous recombination repair gene alterations.
Further detailed effectiveness metrics were provided in the comprehensive analysis of the study.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Final analysis shows effectiveness of niraparib with abiraterone acetate in metastatic castration-resistant prostate cancer, suggesting potential benefits for this population.

Abstract

United States National Library of Medicine (https://clinicaltrials.gov); NCT03748641.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ye et al. (2026) studied this question.

synapsesocial.com/papers/69eb0ac4553a5433e34b4b93 https://doi.org/10.1111/iju.70455

View at Publisher

Ask AI

Bookmark

Share

Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Niraparib With Abiraterone Acetate Plus Prednisone as First‐Line Therapy in Patients With Metastatic Castration‐Resistant Prostate Cancer With Homologous Recombination Repair Gene Alterations: Final Analysis of the Asian Subgroup From the MAGNITUDE Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from International Journal of Urology

Keep reading

More related papers

More from International Journal of Urology